Chaudhry UA, Ezekowitz MD, Gracely EJ, et al. - Approval has been granted to use of low dose direct acting oral anticoagulants (LDDOACS) in elderly atrial Fibrillation (AF) patients but there exists limited information, thus, researchers undertook this retrospective study wherein they obtained baseline features and results in AF patients ≥ 80 prescribed LDDOAC or warfarin (W), from a multidisciplinary practice between 1/1/11 (First LDDOAC available) and 5/31/17. There were 9660 AF patients, of which 514 ≥ 80 were administered a LDDOAC and 422 W. No clinically significant differences were found among those patients taking Dabigatran 75 mgs BID (D), Rivaroxaban 15mgs (R) or Apixaban 2.5mgs BID (A). CNS bleeds were noted to be 2.2 for D, 1.7 for R and 0.8%/yr. for A. Major bleeding was reported to be 14.3 for D, 14.1 for R and 9.1%/yr. for A. The observed mortality was 5.5 for D, 4.2 for R and 9.5% for A. In half the patients, continuation of their assigned anticoagulant was evident. Findings revealed similar and low stroke/systemic embolism and intracranial bleed rates. Differences in major bleeds and deaths were evident between groups, which highlights the requirement for prospective randomized trials in this increasing population with AF.